Drug Interactions between Braftovi and Multitrace-4 Pediatric
This report displays the potential drug interactions for the following 2 drugs:
- Braftovi (encorafenib)
- Multitrace-4 Pediatric (trace elements)
Interactions between your drugs
No interactions were found between Braftovi and Multitrace-4 Pediatric. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Braftovi
A total of 618 drugs are known to interact with Braftovi.
- Braftovi is in the drug class multikinase inhibitors.
- Braftovi is used to treat the following conditions:
Multitrace-4 Pediatric
A total of 189 drugs are known to interact with Multitrace-4 Pediatric.
- Multitrace-4 pediatric is in the drug class intravenous nutritional products.
- Multitrace-4 pediatric is used to treat Parenteral Nutrition.
Drug and food interactions
encorafenib food
Applies to: Braftovi (encorafenib)
GENERALLY AVOID: Coadministration with potent or moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of encorafenib, which is primarily metabolized by the isoenzyme. When a single 50 mg dose of encorafenib (equivalent to 0.1 times the recommended dose) was administered with posaconazole, a potent CYP450 3A4 inhibitor, encorafenib peak plasma concentration (Cmax) increased by 68% and systemic exposure (AUC) increased by 3-fold. When the same dose of encorafenib was administered with diltiazem, a moderate CYP450 3A4 inhibitor, encorafenib Cmax increased by 45% and AUC increased by 2-fold. Increased exposure to encorafenib may increase the risk of serious and life-threatening adverse effects such as hemorrhage, uveitis, QT prolongation, hepatotoxicity, dermatologic reactions, and new malignancies.
MANAGEMENT: Concomitant use of encorafenib with grapefruit or grapefruit juice should generally be avoided. If coadministration is required, the manufacturer recommends reducing the encorafenib dose to one-third of the dose used prior to addition of a potent CYP450 3A4 inhibitor or one-half of the dose used prior to addition of a moderate CYP450 3A4 inhibitor. After the inhibitor has been discontinued for 3 to 5 elimination half-lives, the encorafenib dose that was taken prior to initiating the inhibitor may be resumed.
References
- (2018) "Product Information. Braftovi (encorafenib)." Array BioPharma Inc.
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.